The UK charity for WM & LPL – a rare type of blood cancer

Support Line: 0300 373 8500

Factsheet: How to access zanubrutinib

March 15, 2024

We know patients are concerned about accessing zanubrutinib...

Following the decision from the National Institute for Clinical Excellence (NICE), we know patients are concerned about accessing zanubrutinib. We’ve put together this handy guide to help you access it (and what you need to ask your consultant).

Related Documents

WM and LPL: A Guide to Treatments
Free guide to treatments for Waldenstrom’s macroglobulinaemia (WM) and lymphoplasmacytic lymphoma (LPL), from active monitoring to chemo-immunotherapy.
WMUK Impact Report 2024–25
How we reached, supported and empowered more people living with WM and LPL than ever before.
non-IgM LPL Fact Sheet
Our guide for those diagnosed with LPL